Illumina UBS Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good morning. I'm Doug Schenkel from UBS. It's my pleasure to welcome Jacob Thaysen and Ankur Dhingra, CEO and CFO of Illumina, respectively. Thank you both for being here with us.
Thanks for inviting. Yeah, pleasure to be here.
Today, we want to focus our discussion on five areas, just to give everybody a roadmap. We want to talk about growth, we want to talk about results from Q3, and how that affects how we should think about Q4 and the path into 2027. We want to unpack a bit more on what's going on with core sequencing, clinical and research demand, and then try to get into a little bit of strategy. An ambitious roadmap, but we're going to get there.
Good. Jacob, let's start with demand today, and what needs to happen to deliver on the long-term growth framework.
Starting with the state of the business, how would you characterize end market demand and customer purchase behavior heading into 2027?
All right. Thanks for that, and let me start by saying, this year has been fantastic for Illumina. We have had great momentum in the market. Q3 went very well. We were beating the expectations for Q3 and also raised for Q4, so raised for the full year, both on the top line and the bottom line. We feel really good where we are. We continue to see very strong demand in the clinical space, where we have seen consumables grow in the mid-teens. We have placed more instrument the last 12 months, or the X instrument the last 12 months, than we did in the first year of the launch, which is, I think, have never happened before.
I was going to say, I don't remember that happening at any point in the Illumina NGS era.
Yeah. Some of the drivers behind that is, as I mentioned, first and foremost, the clinicals business continues to have strong momentum. Also, we went out here earlier this year and communicated a roadmap on innovation that will continue to really build out the opportunities you can do on the NovaSeq X, both in terms of better flow cells, more capacity on flow cells, but also other innovations. I think customers are seeing that, is that when you bet on Illumina, bet on the NovaSeq X, you are part of an innovation life cycle also. We're excited about that. The research market is still weaker. It is improving sequentially, but it's still the clinical that is growing.
With that, what we went out in 2024, when we had our last time we were out then and talk about our strategy, we went out saying we would step ourself into growth, where we believed that 2025 would be the mid-single digit growth, and then 20, excuse me, 2026 would be mid-single digit, and 2027 then would step ourself into high single digit growth. We are still on that trajectory. It is going to be our consumables that will be the main driver of that into 2027, and we see that momentum. We also communicated, committed to an expansion of our margins of 500 basis points ex-M&A, and we are on track to deliver that also.
To be clear, 2027, we are very much on track for high single-digit revenue growth and at least 25.5% operating margin as a starting point.
Well, I am not here to commit to any guidance for 2027, but that is what we communicated in our strategy, and we are on that trajectory.
Okay. Very quickly on academic government. Building off of what you just described, post-election, it has only been a few days, but I would imagine the psychology of releasing budgets potentially has the potential to get better.
Yeah. I think overall, I mean, I think in what we are seeing, of course, academic is a part of the research segment itself in how we talk about it externally. There's no doubt that we have seen over the last month that the grants are flowing now in the system, and I think there is expectation also at least that the grants next year would be in the same level as this year. Maybe improvement, we don't know, but it's likely going to be in that area. So I think that part is better under control. What is still not, you can call it the algorithm for the individual PI, is still not fully known.
Right. Who's actually getting the grant?
If I'm usually getting a few grants per year, am I getting the same level of grants? So I think that uncertainty still keeps the PIs from making longer-term decisions, especially purchasing instruments and other things that is still weaker. But I think you need a few more quarters where they get comfortable in how these so-called grant algorithms work, and then we'll be in better space. But at this point, we're not calling out that this turns of improving in the market. We're just seeing that that is eventually going to happen.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
